Alectos Therapeutics is a privately held pharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics for the treatment of human disease. We focus on preclinical drug development, target validation, hit-to-lead optimization, and IND-enabling studies. Alectos develops innovative new strategies to address medical conditions for which there are no effective treatments.
Our most advanced program is directed towards development of first-in-class agents that modulate the O-GlcNAcase (OGA) enzyme as a disease-modifying therapy for treatment of Progressive Supranuclear Palsy, Alzheimer’s disease, and other neurodegenerative disorders; this program is partnered with Merck. As part of its pipeline, Alectos is also advancing discovery-stage programs in immuno-oncology and Parkinson’s disease.
The Discovery and Characterization of [18F]MK‐8553, a Novel PET Tracer for Imaging O‐GlcNAcase (OGA)
[18F]MK-8553 is a high affinity, selective OGA inhibitor with properties suitable for imaging OGA and determining central enzyme occupancy in both preclinical [...]
Alectos Therapeutics Announces FDA Orphan Drug Designation for MK-8719: An Investigational Small-molecule OGA Inhibitor for Treatment of Progressive Supranuclear Palsy
Advances Novel Tau-directed Strategy for Treating Neurodegenerative Disease Phase 1 Clinical Trial Completed Vancouver, British Columbia (April 20, 2016) – Alectos Therapeutics [...]
Preclinical Data Disclosed for Tau PET Tracer MK-6240: A Potential Clinical Biomarker for OGA Inhibitor MK-8719
Apr 18, 2016 – Alectos Therapeutics partner Merck, known as MSD outside the U.S. and Canada, today disclosed preclinical data for potential clinical [...]
Feb 11, 2016 – Alectos today announced its support for NSERC funding for the group of Prof. A.J. Bennet at Simon Fraser [...]
Feb 17, 2015 – Alectos today announced its support as an industry partner in the new Canadian Glycomics Network (GlycoNet), unveiled this [...]